Theralase Technologies (CVE:TLT) Shares Up 3.8% – Still a Buy?

Theralase Technologies Inc. (CVE:TLT) rose 3.8% during trading on Tuesday . The stock traded as high as C$0.27 and last traded at C$0.27. Approximately 43,002 shares traded hands during mid-day trading, a decline of 82% from the average daily volume of 232,504 shares. The stock had previously closed at C$0.26.

Theralase Technologies Trading Up 3.8%

The company has a market capitalization of C$79.83 million, a price-to-earnings ratio of -19.29 and a beta of -0.57. The company has a debt-to-equity ratio of 22.13, a quick ratio of 3.40 and a current ratio of 1.37. The business’s 50-day simple moving average is C$0.25 and its 200-day simple moving average is C$0.27.

Theralase Technologies Company Profile

Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.